We are live on
!
Find out more
MWNA
Marshall Wace North America Portfolio holdings
AUM
$23.5B
1-Year Est. Return
46.46%
This Fund
S&P 500
This Quarter
Est. Return
+0.24%
1 Year Est. Return
+46.46%
3 Year Est. Return
+109.4%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$17.6B
AUM Growth
+$1.47B
(+9.1%)
Cap. Flow
+$1.6B
Cap. Flow
% of AUM
9.12%
Top 10 Holdings %
Top 10 Hldgs %
17.57%
Holding
1,695
New
602
Increased
310
Reduced
364
Closed
414
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$207M |
| 2 |
Pfizer
PFE
|
+$171M |
| 3 |
Johnson & Johnson
JNJ
|
+$140M |
| 4 |
SS&C Technologies
SSNC
|
+$132M |
| 5 |
Microsoft
MSFT
|
+$131M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abbott
ABT
|
+$158M |
| 2 |
Meta Platforms (Facebook)
META
|
+$120M |
| 3 |
Booking.com
BKNG
|
+$106M |
| 4 |
Merck
MRK
|
+$93.9M |
| 5 |
Idexx Laboratories
IDXX
|
+$92.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 25.54% |
| 2 | Technology | 21.21% |
| 3 | Consumer Discretionary | 13.38% |
| 4 | Industrials | 12.45% |
| 5 | Financials | 7.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
GBT
851
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $378K | ﹤0.01% |
+7,790
| New | +$406K |
|
852
BorgWarner
BWA
$13.9B
| $377K | ﹤0.01% |
11,675
-164,652
| -93% | -$5.3M |
|
|
DOC
853
DELISTED
PHYSICIANS REALTY TRUST
DOC
| $377K | ﹤0.01% |
+21,256
| New | +$369K |
|
854
MarketAxess Holdings
MKTX
$5.72B
| $375K | ﹤0.01% |
+1,145
| New | +$410K |
|
855
Hamilton Lane
HLNE
$5.57B
| $374K | ﹤0.01% |
+6,568
| New | +$386K |
|
|
MXIM
856
DELISTED
Maxim Integrated Products
MXIM
| $371K | ﹤0.01% |
+6,398
| New | +$371K |
|
857
Grupo Cibest SA
CIB
$21.1B
| $370K | ﹤0.01% |
+7,475
| New | +$377K |
|
858
Fox Class B
FOX
$23.9B
| $363K | ﹤0.01% |
+11,514
| New | +$398K |
|
859
Amkor Technology
AMKR
$13.7B
| $362K | ﹤0.01% |
+39,741
| New | +$341K |
|
|
HAYN
860
DELISTED
Haynes International, Inc.
HAYN
| $361K | ﹤0.01% |
+10,086
| New | +$319K |
|
|
GOOD
861
Gladstone Commercial Corp
GOOD
$627M
| $360K | ﹤0.01% |
+15,336
| New | +$340K |
|
|
VIVO
862
DELISTED
Meridian Bioscience Inc
VIVO
| $358K | ﹤0.01% |
+37,740
| New | +$398K |
|
|
TGNA
863
DELISTED
TEGNA Inc
TGNA
| $354K | ﹤0.01% |
+22,794
| New | +$344K |
|
864
Comtech Telecommunications
CMTL
$51.8M
| $353K | ﹤0.01% |
+10,861
| New | +$309K |
|
865
Elevance Health
ELV
$85.5B
| $353K | ﹤0.01% |
1,468
-16,304
| -92% | -$4.47M |
|
866
Evercore
EVR
$11.8B
| $349K | ﹤0.01% |
4,363
-1,407
| -24% | -$117K |
|
|
QTNT
867
DELISTED
Quotient Limited Ordinary Shares
QTNT
| $340K | ﹤0.01% |
+1,093
| New | +$421K |
|
868
News Corp Class A
NWSA
$15.4B
| $338K | ﹤0.01% |
+24,258
| New | +$331K |
|
869
BridgeBio Pharma
BBIO
$16.5B
| $337K | ﹤0.01% |
15,707
-34,272
| -69% | -$948K |
|
870
Horace Mann Educators
HMN
$2.11B
| $336K | ﹤0.01% |
+7,269
| New | +$318K |
|
|
NBLX
871
DELISTED
Noble Midstream Partners LP
NBLX
| $335K | ﹤0.01% |
13,859
+6,034
| +77% | +$168K |
|
|
RST
872
DELISTED
ROSETTA STONE INC
RST
| $334K | ﹤0.01% |
+19,217
| New | +$387K |
|
|
BRKL
873
DELISTED
Brookline Bancorp
BRKL
| $328K | ﹤0.01% |
+22,234
| New | +$322K |
|
874
Liberty Energy
LBRT
$3.25B
| $327K | ﹤0.01% |
+30,164
| New | +$370K |
|
875
Palomar
PLMR
$3.45B
| $327K | ﹤0.01% |
8,294
-34,870
| -81% | -$1.09M |
|
Similar funds
TGHSA
PAM
HB
MWA
3SCA
HFCIV
DVC
NAM
Marshall Wace North America's Q3 2019 Portfolio in Review
As of Q3 2019, Marshall Wace North America held 1,695 positions worth $17.6B, up 9.1% from $16.1B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Marshall Wace North America deployed $1.6B of net new capital in Q3 2019, opening 602 new positions and adding to 310 existing holdings. Its largest new stake was Johnson & Johnson: 1,065,531 shares worth $138M.
By sector, the portfolio is most concentrated in Healthcare at 26% of assets, down from 28% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Meta Platforms (Facebook), an estimated $120M trimmed.
- Marshall Wace North America's largest Q3 2019 buy was Johnson & Johnson: 1,065,531 shares worth $138M.
- Marshall Wace North America added most to Apple in Q3 2019, an estimated $207M increase.
- Marshall Wace North America's biggest Q3 2019 reduction was Meta Platforms (Facebook), cutting an estimated $120M.
- Marshall Wace North America fully exited Abbott in Q3 2019, selling an estimated $158M.
- Marshall Wace North America's ten largest holdings make up 18% of its $17.6B portfolio in Q3 2019.
- Marshall Wace North America opened 602 new positions and closed 414 in Q3 2019.
- Marshall Wace North America's portfolio value rose 9.1% quarter-over-quarter to $17.6B.
Based on Marshall Wace North America's 13F filing for Q3 2019, filed 14 Nov 2019.